S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
66,000% upside on tiny biotech? (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
66,000% upside on tiny biotech? (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
66,000% upside on tiny biotech? (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
66,000% upside on tiny biotech? (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
66,000% upside on tiny biotech? (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
66,000% upside on tiny biotech? (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
S&P 500   4,975.51
DOW   38,563.80
QQQ   427.32
Higher VIX just made Realty Income’s 6% dividend better
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE! (Ad)
Super Micro Computer: Overbought, undervalued or mispriced?
Booking stock is the discounted growth story in travel stocks
66,000% upside on tiny biotech? (Ad)
3 E-VTOL stocks: Which ones can fly higher in 2024?
Capital One's bid for Discover carries expectation that Americans won't slow credit card use
66,000% upside on tiny biotech? (Ad)
Walmart’s uptrend is intact; buy it when it dips
XPeng stock just got a target boost, analysts say it could double
OTCMKTS:DSNKY

Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

$33.40
+0.82 (+2.52%)
(As of 02/20/2024 ET)
Today's Range
$32.81
$33.50
50-Day Range
$26.80
$33.40
52-Week Range
$23.72
$37.57
Volume
48,019 shs
Average Volume
76,854 shs
Market Capitalization
N/A
P/E Ratio
0.29
Dividend Yield
67.27%
Price Target
N/A

Daiichi Sankyo MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.26mentions of Daiichi Sankyo in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.36 out of 5 stars


DSNKY stock logo

About Daiichi Sankyo Stock (OTCMKTS:DSNKY)

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

DSNKY Stock Price History

DSNKY Stock News Headlines

Daiichi Sankyo Co Ltd 4568
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Q4 2023 Merck & Co Inc Earnings Call
What's Going On With Pfizer Stock Today?
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Daiichi Sankyo Co., Ltd. (4568)
Nikkei Falls 0.5%, Dragged by Electronics, Retail Stocks
See More Headlines
Receive DSNKY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
OTCMKTS:DSNKY
CIK
N/A
Fax
N/A
Employees
17,435
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Sunao Manabe D.V.M. (Age 70)
    Ph.D., Group CEO & Executive Chairperson
    Comp: $1.9M
  • Mr. Hiroyuki Okuzawa (Age 62)
    President, COO & Representative Director
    Comp: $746.35k
  • Mr. Masahiko Ohtsuki (Age 65)
    Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director
    Comp: $746.35k
  • Dr. Shoji Hirashima (Age 63)
    Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director
    Comp: $807.41k
  • Mr. Koji Ogawa
    Managing Executive Officer, Head of Global Corporate Planning & Management and CFO
  • Hiroto Kashiwase
    Managing Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQ
  • Naoto Tsukaguchi
    Gen. Counsel, Corp. Officer, Head of Global Leg., IP, Global Compl. and Risk & VP of Leg. Aff. Dept.
  • Kentaro Asakura
    Vice President of Corporate Communications Department
  • Ms. Marielle Cohard-Radice M.D.
    Global Head of Development
  • Akio Sakurai
    Corporate Officer, Head of Sales and Marketing Div. & Japan Business Unit














DSNKY Stock Analysis - Frequently Asked Questions

Should I buy or sell Daiichi Sankyo stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daiichi Sankyo in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" DSNKY shares.
View DSNKY analyst ratings
or view top-rated stocks.

How have DSNKY shares performed in 2024?

Daiichi Sankyo's stock was trading at $27.35 at the beginning of 2024. Since then, DSNKY stock has increased by 22.1% and is now trading at $33.40.
View the best growth stocks for 2024 here
.

Are investors shorting Daiichi Sankyo?

Daiichi Sankyo saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 21,300 shares, an increase of 8.1% from the December 31st total of 19,700 shares. Based on an average daily volume of 186,300 shares, the days-to-cover ratio is currently 0.1 days.
View Daiichi Sankyo's Short Interest
.

Is Daiichi Sankyo a good dividend stock?

Daiichi Sankyo (OTCMKTS:DSNKY) pays an annual dividend of $22.47 per share and currently has a dividend yield of 3.12%. The dividend payout ratio is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Daiichi Sankyo?

Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:DSNKY) was last updated on 2/21/2024 by MarketBeat.com Staff